We have previously reported that ATO could inhibit the RA synovial angiogenesis via the VEGF functional module; therefore, the results of the present study undoubtedly provided an in-depth insight into the antiangiogenic activities of ATO, revealing a new level of diversity in the regulatory mechanisms of ATO therapy on diseases. This evidence concerns the gene VEGFA and rheumatoid arthritis.